Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Genome Sequencing Enables Discovery of Mutation Leading to Prader-Willi Syndrome, with Link to Autism

By BiotechDaily International staff writers
Posted on 09 Oct 2013
Image: A look inside the human genome-sequencing lab at Complete Genomics (Photo courtesy of Complete Genomics).
Image: A look inside the human genome-sequencing lab at Complete Genomics (Photo courtesy of Complete Genomics).
Highly accurate whole genome sequencing technology has played a pivotal role in identifying a mutation involved in causing Prader-Willi Syndrome, helping to resolve a diagnostic conundrum.

Prader-Willi Syndrome (PWS) is a rare (around 1:15,000) genetic disorder that leads to poor muscle tone, low levels of sex hormones, and a constant feeling of hunger often leading to obesity. It occurs in males and females equally, and affects all races. The whole genome sequencing technology of Complete Genomics, Inc. (Mountain View, CA, USA), subsidiary of BGI-Shenzhen, was used in the identification of a point mutation causing PWS, a discovery that helped resolve a diagnostic conundrum for four young male patients who tested PWS-negative as infants.

The study, published September 29, 2013, in the journal Nature Genetics, is a collaborative effort of researchers at Baylor College of Medicine (BCM; Houston, TX, USA), the Jan and Dan Duncan Neurological Research Institute (Duncan NRI; Houston, TX, USA), and the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (Houston, TX, USA).

The first patient tested PWS negative by age one year, but over the next 12 years began to manifest some of the typical PWS symptoms. Complete Genomics’ sequencing service was used in an analysis determining the genetic basis of his symptoms: a single mutation, a base deletion, was identified in the protein-coding MAGEL2 gene, in a section of chromosome 15 previously linked to PWS, and in a difficult to sequence GC rich region. It proved to be a frame-shift deletion, truncating mutation, which disrupts the MAGEL2 protein product. As MAGEL2 is only known to be expressed from the paternal gene allele (the maternal allele being silenced), it was also important to determine whether the mutation was on the maternal or paternal version of chromosome 15. In this case, the MAGEL2 mutation was confirmed to be on the paternal allele using a modified version of Complete Genomics’ Long Fragment Read technology.

To further investigate MAGEL2’s role in PLW, the researchers reviewed over 1,200 exome sequencing reports, searching for other patients with loss-of-function mutations in that gene. Three additional patients were identified – one with classic PWS, the other two with PWS-like symptoms. However, all had negative PWS tests as infants. All four patients were also diagnosed with autism spectrum disorder (ASD) and intellectual disability. These findings suggest that MAGEL2 is a new gene causing complex ASD and that MAGEL2 loss of function can contribute to several aspects of the PWS phenotype.

“This is the first study to show that point mutations can cause Prader-Willi Syndrome,” said Dr. Schaaf, assistant professor of molecular and human genetics at BCM and faculty member at the Duncan NRI; “This is an important development that increases our understanding of this complex disorder, and also gives four boys a diagnosis, which they and their parents have sought for many years.” “It also underscores the importance of being able to distinguish between maternal and paternal variants because only patients who had point mutations on the paternal copy of the MAGEL2 gene would experience the disorder,” added Dr. Brock Peters, director of research at Complete Genomics.

Related Links:

Complete Genomics
Baylor College of Medicine
The Jan and Dan Duncan Neurological Research Institute (of Texas Children's Hospital)



Channels

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.